Biohit’s key markets are Europe and Asia. Biohit is working to build a committed and focused distributor and partner network and to identify potential new distributors.
New agreements for diagnostic products are being prepared with distributors specialising in gastroenterology. Partners are also being sought for Acetium products, with the objective of establishing co-operation covering sales and marketing, as well as manufacture and regional research in selected areas. Once its products have been registered, Biohit helps distributors with, for example, commerzialisation and user training as required in each country.
INNOVATIONS AS BUSINESS SPEARHEADS
Biohit’s product range encompasses tests, instruments and analysis systems for laboratories. Biohit has also introduced its unique range of Acetium products, which bind carcinogenic acetaldehyde in the stomach.
Primary healthcare forms the main user base for Biohit’s GastroPanel® examination (for stomach health) and the ColonView quick test (to diagnose the risks of colorectal cancer). Biohit’s quick tests for lactose intolerance and H. pylori are also suitable for use in specialised healthcare. In addition to these tests, the company also markets and sells its own GastroPanel® laboratories with varying capacities. They include GastroPanel® examination kits, liquid handling equipment, instruments, and software. Biohit purchases any liquid handling products required for its diagnostics products and laboratories from Sartorius, which acquired Biohit’s liquid handling business. The GastroPanel® laboratory concept promotes the effective use of GastroPanel® examinations.
The Healthy Stomach Initiative
The Healthy Stomach Initiative’s international research team recommends the use of the GastroPanel® examination’s biomarkers for the diagnosis and screening of those suffering from abdominal complaints and asymptomatic H. pylori infection, and for atrophic gastritis resulting from H. pylori infection or an autoimmune disease, when it is not safe to use the alternative procedure, the 13C urea breath test. 20–40 % of the population in Western countries suffer from abdominal complaints. Diseases of the gastrointestinal tract are a major source of healthcare costs all across the globe. Many examination and treatment practices are also insufficient and outdated. Read more at www.hsinitiative.org.
New treatment culture, unique solutions
GastroPanel® represents the latest in safety, cost-effectiveness, and technological advancement in the field. It doesn’t exhibit any of the serious medical issues as the following tests, which can lead to malpractice and even needless deaths from gastric cancer.
On the basis of the Finnish Setti study (Varis et al., 2000), an estimated 250–300 gastric cancer deaths among the over-50s could be prevented in Finland each year. These deaths could be preventable by using GastroPanel® to screen all elderly people for atrophic gastritis, and all suspected H. pylori positive patients in particular. Gastroscopy can be conducted on at-risk patients to diagnose early-stage gastric cancers and precancerous lesions while the diseases are still at an asymptomatic and curable stage. In addition to assessing the risk of gastric and oesophageal cancer, GastroPanel® screening, diagnostics and examinations provide a lot more reliable and valuable information.